Patent ID: 11951112
Assignee: MAXIM MASIUTIN
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating a patient with late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency caused by a mutation in the CYP21A2 gene comprising:
administering, to the patient, daily doses of glucocorticoids comprising:
a dose of a short-acting glucocorticoid comprising hydrocortisone in the morning; and
a dose of a long-acting glucocorticoid comprising dexamethasone in the evening,
wherein the doses are optimized for the patient to counterbalance adverse reactions;

measuring a serum level of sex hormone binding globulin (SHBG) of the patient; and
adjusting the daily doses of the glucocorticoids based on the measured serum level of SHBG, wherein said adjusting comprises:
decreasing the dose of the long-acting glucocorticoid if the serum level of SHBG has reached a level of less than 120 nmol/L for women, or less than 49 nmol/L for men under 50 years of age, or less than 70 nmol/L for men over 50 years of age, otherwise the daily dose of dexamethasone is increased.